Jerusalem, Israel, July 27, 2017
Immunity Pharma, a neurology-focused biopharmaceutical company, announced today that Dr. Ilana Cohen has joined Immunity Pharma as its Vice President of Research and Development. Dr. Cohen earned her PhD in neurobiology from the Weismann Institute of Science, Israel and did her postdoctoral training in the Department of Neurobiology at Stanford University. Dr. Ilana Cohen brings with her over 20 years of scientific leadership as well as management experience in the pharmaceuticals and biotechnology industries. Prior to joining Immunity Pharma Dr. Cohen held leadership positions in InSight Biopharmaceuticals and in Peptor. Ilana is one of Immunity Pharma's founders and she now joins the company in full capacity.
“Immunity pharma has a novel technology for treating neurodegenerative disorders by upregulating pro-survival signaling pathways in variety of cells, including neurons. The promising results obtained from over two years of companionate IPL344 treatment of an advanced ALS patient supports our planed clinical trials” said Dr. Ilana Cohen.
"Ilana is an expert in neurobiology with vast experience in drug development (including peptides) and in the development of bioassays including biomarker identification and qualification methods. Her scientific and managerial experience will be of great value as we clinically evaluate IPL344 in ALS and other neurodegenerative diseases" said Eran Ovadia, Immunity Pharma's founder and CEO.
About IPL344
IPL344 is Immunity Pharma lead drug candidate. IPL344 activates the PI3K-Akt signaling pathway in a variety of cells, including neurons, inducing pro-survival and anti-inflammatory processes. IPL344 is being developed as an intravenous injection for the treatment of ALS. IPL344 is planned to enter an open-label Phase 1/2a clinical trial in ALS patients.
About Immunity Pharma
Immunity Pharma Ltd. (IPL) is a privately-held clinical-stage neurology-focused biopharmaceutical company that develops therapies for neurodegenerative diseases, with an initial focus on Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. IPL’s drugs are biologically active peptides that stimulate therapeutic cell-signaling processes which are down-regulated in neurodegenerative diseases. These drugs mitigate progression of neurodegenerative diseases by inducing survival-supporting processes, including reduction of inflammation and reduction of programed cell death (apoptosis).
For more information please visit www.immunitypharma.com